Corey Pelletier

Articles by Corey Pelletier

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

ByElyse Swallow,Jessica Maitland,Kirthana Sarathy,Ellen Sears,Yasir Nagarwala,Janelle DePalantino,Eric Kruep,Corey Pelletier,Sebastian Kloss,Tomer Wasserman

April 18th 2025

37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model

37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model

ByGregory Vidal, MD, PhD,Frank Cinfio,Jack Badaracco,Corey Pelletier,Matthew Gitlin

June 22nd 2024

Latest Updated Articles

Trending on CancerNetwork

FDA Approves TLX101-Px for PET Imaging in Patients With Glioma

Debating CAR T-Cell Therapy Vs Bispecifics at First Relapse in Myeloma

FLT3 Inhibitor Strategies Continue to Improve Survival Across AML Settings

Perioperative Durvalumab Combo Boosts Survival in Resectable Gastric Cancer

Which Lung Cancer Presentations Will Move the Needle at WCLC 2026?